The study on combination effect of artesunate and lenalidomide on the treatment of bortezomib-resistant multi-ple myeloma cell line
Abstract：Objective To investigate the combination effect of artesunate and lenalidomide on the proliferation of bortezomib-resistant multiple myeloma cell line MM .1R, and its molecular mechanism .Methods MM.1R cells were cultured in RPMI 1640 and treated with DMSO (control group), lenalidomide (20 μmol/L), artesunate (25 μg/mL), or lenalidomide (20μmol/L) plus artesunate (25μg/mL), separately.After 24 or 48 h, the cell proliferation rates were assessed by MTT assay, and the NF-κB (P65), Bcl-xl, Mcl-1, p-Bad, and P-gp protein levels were measured by Western blot .Results The inhibitory rate of cell proliferation was 15.16%by lenalidomide for 24 h, 28.28%by lena-lidomide for 48 h, 45.98%by artesunate for 24 h, 17.19%by artesunate for 24 h, 34.53%by lenalidomide plus artesu-nate for 24 h, or 65.16%by lenalidomide plus artesunate for 48 h (P<0.05).NF-κB (P65), Bcl-xl, Mcl-1, p-Bad, and P-gp proteins were down -regulated by lenalidomide plus artesunate treatment in a time -dependent manner . Conclusion Both artesunate and lenalidomide inhibit MM .1R cell proliferation .Combination of artesunate with lenalido-mide can enlarge this effect through down -regulating NF-κB (P65), Bcl-xl, Mcl-1, p-Bad, and P-gp.
Keywords：artesunatelenalidomidemultiple myelomadrug-assistant
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 501-504 )